As the market grows, it becomes necessary to understand efficacy, costs, and alternatives.

As opioid prescribing continues to decline, more nuanced and population-specific drug trends emerge as cost drivers.

Elyxyb (celecoxib) is an NSAID for the acute treatment of migraine with or without aura.

Anjeso and a new Advil formulation target pain, while Nurtec™ and Vyepti™ target migraines.

Migraine, arthritis, and insomnia drug approvals, and a gabapentinoids safety warning.

A new wave of drugs that suppress CGRP proteins to reduce migraines could be on the horizon.

The FDA recently approved drugs to treat opioid dependence, migraines, and rheumatoid arthritis.